Abstract:Introduction: Epigenetics play a vital role in stratifying CNS tumors and gliomas. The importance of studying Secreted frizzled-related protein 4 (SFRP4) in gliomas is to improve diffuse glioma methylation profiling. Here we examined the methylation status of SFRP4 promoter and the level of its protein expression in diffuse gliomas WHO grades 2–4. Methods: SFRP4 expression was detected by immunohistochemistry and evaluated semi-quantitatively. In the tumor hot-spot area, the intensity of protein expression in 200 cells was determined using ImageJ (National Institutes of Health, United States). The assessment of immunopositivity was based on the IRS score (Immunoreactivity Score). Promoter methylation was examined by methylation specific-PCR (MSP) in fifty-one diffuse glioma samples and appropriate controls. Isolated DNA was treated with bisulfite conversion and afterwards used for MSP. Public databases (cBioPortal, COSMIC and LOVD) were searched to corroborate the results. Results and discussion: SFRP4 protein expression in glioblastomas was very weak or non-existent in 86.7% of samples, moderate in 13.3%, while strong expression was not observed. The increase in astrocytoma grade resulted in SFRP4 protein decrease ( p = 0.008), indicating the loss of its antagonistic role in Wnt signaling. Promoter methylation of SFRP4 gene was found in 16.3% of cases. Astrocytomas grade 2 had significantly more methylated cases compared to grade 3 astrocytomas ( p = 0.004) and glioblastomas ( p < 0.001), which may indicate temporal niche of methylation in grade 2. Furthermore, the expression levels of SFRP4 were high in samples with methylated SFRP4 promoter and low or missing in unmethylated cases (Pearson's R = −0.413; p = 0.003). We also investigated the association of SFRP4 changes to key Wnt regulators GSK3β and DKK3 and established a positive correlation between methylations of SFRP4 and GSK3β (Pearson's R = 0.323; p = 0.03). Furthermore, SFRP4 expression was correlated to unmethylated DKK3 (Chi square = 7.254; p = 0.027) indication that Wnt signaling antagonist is associated to negative regulator's demethylation. Conclusion: The study contributes to the recognition of the significance of epigenetic changes in diffuse glioma indicating that restoring SFRP4 protein holds potential as therapeutic avenue. Reduced expression of SFRP4 in glioblastomas, not following promoter methylation pattern, suggests another mechanism, possible global methylation, that turns off SFRP4 expression in higher grades.

Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.

Expression of Dedifferentiation Markers and Multilineage Markers in U251 Glioblastoma Cells with Silenced EGFR and FGFR Genes.

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

Elevated Levels of P-Mnk1, P-Eif4e and P-P70s6k Proteins Are Associated with Tumor Recurrence and Poor Prognosis in Astrocytomas.

Overexpression of FAK promotes Ras activity through the formation of a FAK/p120RasGAP complex in malignant astrocytoma cells

[High expression of fragile X mental retardation protein inhibits ferroptosis of colorectal tumor cells by activating the RAS/MAPK signaling pathway]

Excessive astrocyte-derived neurotrophin-3 contributes to the abnormal neuronal dendritic development in a mouse model of fragile X syndrome.

Fragile X Mental Retardation Protein Regulates Proliferation and Differentiation of Adult Neural Stem/Progenitor Cells

Glioma Cell Proliferation Controlled by ERK Activity-Dependent Surface Expression of PDGFRA

Over-Expression of Cofilin-1 and Phosphoglycerate Kinase 1 in Astrocytomas Involved in Pathogenesis of Radioresistance

Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β-catenin, and mTOR signaling during corticogenesis

Prognostic Roles for Fibroblast Growth Factor Receptor Family Members in Malignant Peripheral Nerve Sheath Tumor

SFRP4 protein expression is reduced in high grade astrocytomas which is not caused by the methylation of its promoter

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome

Astrocyte‐mediated purinergic signaling is upregulated in a mouse model of Fragile X syndrome

P27kip1 and Cyclin D1 Are Necessary for Focal Adhesion Kinase Regulation of Cell Cycle Progression in Glioblastoma Cells Propagated in Vitro and in Vivo in the Scid Mouse Brain.

Elevated Fras1-related extracellular matrix 3 in isocitrate dehydrogenase 1-mutant astrocytoma World Health Organization grade 4 predicts favorable prognosis in glioma: A bioinformatic and experimental analysis

[Relationship of PTEN, Mdm2 and P53 Expression in Astrocytoma].

Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma

Expression of FAK and Pyk2 in Human Astrocytic Tumors and its Relationship with Angiogenesis